Kailera IPO Raises $625M for Obesity Drug | Pharma and Biotech Daily

About this episode

This episode discusses Kailera's IPO and China's strategic focus on biotechnology and synthetic biology.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore China's burgeoning role in the synthetic biology sector, as outlined in a recent article discussing China's strategic focus on biotechnology within its latest five-year plan. This strategy identifies biomanufacturing, particularly synthetic biology and genetic engineering, as pivotal for China's emerging bioeconomy. The nation's approach frame...

People in this episode

Host: Pharma and BioTech News

Topics covered

• Kailera IPO
• obesity drug
• China biotechnology
• synthetic biology
• biomanufacturing

Keywords

• Kailera
• IPO
• obesity drug
• China
• synthetic biology
• biotechnology
• genetic engineering

Mentioned in this episode

Organizations: Kailera, China, biotechnology, synthetic biology, genetic engineering, bioeconomy

More episodes of Pharma and BioTech Daily

• Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily · June 12, 2026 · 5 min
• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily · June 5, 2026 · 5 min